# **Patient Enrollment and Consent**

Fax Completed Form To (833) 392-8999



Note: If Patient Authorization and Consent is not completed the patient will not have access to Verona Pathway Plus™ Support Programs and Services until it is received.

Date of Birth (MM/DD/YYYY): / /
E-mail:
Authorized Representative Phone:
=

## Patient Services Authorization and Release of Health Information Consent Form

By signing this Authorization and Release of Health Information Consent Form ("Authorization"), I authorize my healthcare provider, my health insurance company, and my pharmacy providers ("Healthcare Entities") and each of their respective representatives, employees, and agents (collectively "Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details (Protected Health Information "PHI") to Verona Pharma, Inc. ("Verona Pharma"), Verona Pathway Plus, its service providers and affiliates (collectively "Verona Pathway Plus") to (i) provide me with support services and related information and materials on any of Verona Pharma products, including, but not limited to, benefit verification, insurance coverage and education, financial assistance services, medication adherence services, (ii) conduct data analytics, market research and other internal business activities including, but not limited to, evaluating the services provided, (iii) enroll me into Verona Pathway Plus Copay Program, if eligible, I understand that Copay Card information will be sent to my specialty pharmacy, along with my prescription. I understand any assistance with my cost-sharing or co-payment for Ohtuvayre  $^{\text{TM}}$  (ensifentrine) will be made in accordance with the Program Terms and Conditions. For purposes of clarification, "Verona Pharma" includes but is not limited to authorized third-party agents involved in administration of Verona Pathway Plus. I understand that I may be contacted by Verona Pathway Plus in the event that I report an adverse event. Once my health information has been disclosed to Verona Pharma, I understand that it may be re-disclosed and federal privacy laws no longer protect the information. However, Verona Pharma agrees to protect my health information by using and disclosing it only for purposes authorized in this Authorization or as required by law or regulations. I understand that my specialty pharmacy provider may receive remuneration from Verona Pharma in exchange for the health information and/or for any support services provided to me. I understand that I am not required to sign this Authorization and that my Healthcare Entities will not condition my treatment, payment, enrollment, or eligibility for benefits on whether I sign this Authorization. This Authorization will expire in 5 years or a shorter period if required by state law, unless I revoke it sooner by writing to 610 Crescent Executive Court, Suite 200 Lake Mary, FL 32746. I understand that revoking my Authorization will terminate my participation in Verona Pathway Plus but will not affect any use of my information that occurred before my request was processed. I am entitled to a copy of this signed Authorization. I also understand that by listing an Authorized Representative above they are authorized to be disclosed my health information and be contacted by Verona Pathway Plus, Healthcare Entities, and Providers in association with my Verona Pharma medication and prescription.

#### **Patient Assistance Program**

I authorize Verona Pathway Plus to verify my eligibility for Patient Assistance Program (PAP), and I understand that such verification may include contacting me or my healthcare provider for additional information and/or reviewing additional financial, insurance, and/or medical information. I understand that, upon request, Verona Pathway Plus will tell me whether an individual consumer report was requested and the name and address of the agency that furnished it. I further understand and authorize Verona Pathway Plus to use any consumer reports about me and information collected from me, along with other information they obtain from public and other sources, to estimate my income in conjunction with the PAP eligibility determination process, if applicable. I further understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid, nor counted toward any true-out-of-pocket (TrOOP) cost, if applicable; and no free product may be sold, traded, or distributed for sale. Additionally, I understand that I must inform the PAP if my financial circumstance, insurance, or any other eligibility criteria changes. I understand that Verona Pharma does not have any obligation to provide the PAP services to me and is not liable in the provision of these services. Verona Pharma reserves the right at any time and without notice to modify or change eligibility criteria or discontinue Verona Pathway Plus.

I authorize Verona Pathway Plus under the Fair Credit Reporting Act to use my demographic information to access reports on my individual credit history from consumer reporting agencies and verify my eligibility for the program.

#### Messaging from Verona Pathway Plus

If I am unavailable when contacted by Verona Pathway Plus, I authorize the following options for a detailed message.

Any Phone Text (Must have cell listed above)

\*I understand a non-detailed message will be left by voicemail, if nothing is selected

#### Other Resources

By checking below, I authorize Verona Pharma, and its affiliates, to contact me by mail, email, fax, text messaging, and or telephone regarding other helpful resources, services, potential market research, and other related topics of interest. I understand that I am not required to provide this consent as a condition of receiving any Verona Pharma medication or Patient Support Services. Note that Verona Pharma will not sell or trade my personal data to any unrelated third party.

Full Terms and Conditions can be found at www.veronapharma.com/terms-and-conditions and our Privacy Policy at www.veronapharma.com/privacy-policy.

I consent to receiving other resources, listed above.

By signing below, I confirm that I have read and understand the Patient Services Authorization and Release of Health Information Consent Form and agree to the terms.

Patient Signature:\_\_\_\_\_\_ Date:\_\_\_\_\_\_



SCAN HERE TO COMPLETE ELECTRONICALLY





Prescription Form
Fax Completed Form To (833) 392-8999



SECTION 1 Patient Information (Required)	Address: C Gender Designation at Birth: Male Female	Date of Birth (MM/DD/YYYY): SSN:  City/State/Zip: Phone:  Birth: Male Female Preferred language: Translator needed?: Yes  Alternate Phone:							
SECTION 2 Insurance Card (Required)	Payer type: Medicare Commercial Medicaid Uninsured  Medical Primary Insurance Secondary/Suppleme Insurance Phone Subscriber ID Group #	Copy of Insurance Card and Demographics are being provided instead of filling out: No Yes  Pharmacy Insurance Name:							
SECTION 3 Prescriber Information (Required)	Prescriber NPI:         State Licer           Address:         Facility Nat	Office Contact:  See:  Contact Fax:  Contact Phone:  Contact Email:							
SECTION 4 Diagnosis (Required)	COPD ICD-10 Codes generally range from J41-J44.9. Other codes may apply.  If YES, does the patient have a standard jet nebulizer?:  Approximate date the patient received standard jet nebulizer.								
SECTION 5 Prescription (Required)	Ohtuvayre Prescription (Includes Welcome Kit)  Rx: Ohtuvayre (ensifentrine) inhalation suspension: 3 mg ensifentrine per 2.5 mL aqueous suspension in unit-dose ampule. Oral inhalation use only.  Directions: 3 mg (one unit-dose ampule) twice daily, once in the morning and once in the evening, administered by oral inhalation using a standard jet nebulizer with a mouthpiece.  Quantity: 30-day supply; 60 ampules (per box); 11 refills or refills								
SECTION 6 Patient Support Programs	Ohtuvayre Bridge Program Prescription Enroll my patient, if eligible Rx: Ohtuvayre (ensifentrine) inhalation suspension: 3 is ensifentrine per 2.5 mL aqueous suspension in united ampule. Oral inhalation use only.  Directions: 3 mg (one unit-dose ampule) twice daily, once in temporaring and once in the evening, administered by inhalation using a Standard Jet Nebulizer with a maximum Guantity: 60 ampules (per box); 30-day supply with up to 1 reference in the evening and once in the evening, administered by inhalation using a Standard Jet Nebulizer with a maximum Guantity: 60 ampules (per box); 30-day supply with up to 1 reference in the evening and once in the evening, administered by inhalation using a Standard Jet Nebulizer; Refill 0	ensifentrine per 2.5 mL aqueous suspension in unit-dose ampule. Oral inhalation use only.  he Directions: 3 mg (one unit-dose ampule) twice daily, once in the oral outhpiece. inhalation using a Standard Jet Nebulizer with a mouthpiece.							
SECTION 7 Prescriber Certification (Required)	to email, fax and telephone. I understand that Verona Pathway Plus may revise, change, or terminate any program services at any time without notice to me.  Prescriber Signature  Date:								

ATTN: Where law requires the prescriber to comply with state-specific prescription requirements, such as electronic prescription. Non-compliance with the specific state requirements may result in outreach to the prescriber.

Electronic Prescriptions to be sent to Phyz, NCPDP: 5828809, Phone: (844) 590-5792



# **Prescription Form**



Fax Completed Form To (833) 392-8999

Patient Name	9:			Date of Birth (MM/DD/YYYY):	Address:			
SECTION 8 Clinical History	Clinical History  Known drug allergies:  Does the patient have an ine Current or tried and failed m  LABA  LAMA  LAMA+LABA  LABA+ICS  LAMA+ICS  LAMA+LABA+ICS	effective inspirate aintenance COP Current Current Current Current Current Current Current	ory flow t D medica OR OR OR OR OR OR	o utilize inhalers?: No Yes ations:  Tried and Failed Product(s):  Tried and Failed Product(s):  Tried and Failed Product(s):  Tried and Failed Product(s):  Tried and Failed Product(s):				
	Other Current OR Tried and Failed Product(s):  How many exacerbations has the patient experienced within the past year?  How many hospitalizations due to the patient's COPD have they had within the past year?  Does the patient have manual dexterity issues to utilize inhalers? No Yes  Other important clinical details:							
SECTION 9 Specialty Pharmacy	Preferred Specialty Pharma No Preference	<b>cy(ies):</b> (If you s	elected a	a pharmacy in which the patient's insuranc DirectRx Specialty Pharmacy	e is out-of-network, the prescription will CVS Specialty Pharmacy	l be triaged to an in-network pharmacy.)  Centerwell Specialty Pharmacy		
SECTION 10 Long-Term Care	Is the patient currently in a long-term care facility?:  No Yes Facility:							
	<ul><li>Have the patient</li><li>If your office has</li></ul>	read page 3 and not received a co	sign to c onfirmati	ce cards (front and back), and copy of pa access support services on fax that the Ohtuvayre Prescription F	orm has been received within one (1) bu			

#### State Requirements:

- Some states will require an additional prescription to be sent directly to the dispensing pharmacy. The patient's Ohtuvayre™ Specialty Pharmacy will outreach to your office Medicare Requirements:
- Medicare requires Clinical Documentation to support the diagnosis of COPD and the need for Ohtuvayre. Clinical Documentation must include at least an electronic signature
- Standard Jet Nebulizer (compressor) information is required for patients when a standard jet nebulizer is not being dispensed with Ohtuvayre. At a minimum the approximate date is required but the pharmacy my need further information for claim submission to CMS

#### For additional forms or information visit ohtuvayrehcp.com

### **Available Support Programs\***

**SECTION 11** 

#### Copay Assistance Program

• Eligible commercially insured patients enrolled in the Verona Pathway Plus Copay Assistance Program may pay as little as \$0 per month<sup>†</sup>

#### Bridge Rx Program

· Available for eligible patients during a coverage delay

#### Patient Assistance Program

- · Patient is required to submit an application and meet program criteria
- · Prescription will expire one (1) year from the written date unless otherwise noted

#### The Ohtuvayre Prescription includes a Welcome Kit

- Understanding Your New Treatment
- · How to Take Ohtuvyare
- Getting Started on Treatment
- \*Patients must be enrolled in Verona Pathway Plus to access these benefits.
- Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.



Call Verona Pathway Plus at (833) 372-8492, Monday to Friday, 8 AM to 8 PM ET, to learn more about how we can help your patients throughout treatment with Ohtuvayre